

Infection control methods for cancer patients undergoing treatment:  
**Infection control measures for prevention of  
fungal infections in neutropenic patients**


**Petra Gastmeier**

# 2010: 300 years Charité hospital Berlin



- 3200 beds
- largest university hospital in Germany
- 3 haematology/ oncology departments

# 2010: 125 years Institute for Hygiene





# Charité University Hospital Berlin



**KISS**  
Krankenhaus-  
Infektions-  
Surveillance-  
System

Institute of Hygiene =  
National Reference Center for  
Surveillance of nosocomial  
infections  
supported by the  
German Ministry of Health

ITS

**KISS**

SARI

DEVICE

**KISS**

HAND

**KISS**

MRSA

**KISS**

AMBU

**KISS**

CDAD

**KISS**

OP

**KISS**

NEO

**KISS**

ONKO

**KISS**

**KISS**

Krankenhaus-  
Infektions-  
Surveillance-  
System

# Endpoints

$$\text{Primary BSI rate} = \frac{\text{Primary BSI cases}}{\text{Neutropenia days}} \times 1000$$

$$\text{Pneumonia rate} = \frac{\text{Pneumonia cases}}{\text{Neutropenia days}} \times 1000$$

- Autologous transplant patients, 25 departments
- Allogenic transplant patients, 19 departments
- Participation is voluntary, confidential data feedback
- [www.nrz-hygiene.de](http://www.nrz-hygiene.de)

# Distribution of infection rates 2006-2010

## Autologous transplant patients

Infection rate	Patients	Infections	Median	75th percentile
Primary BSI / 1000 neutroenic days	2658	373	14.3	19.0
Pneumonia cases / 1000 neutropenic days	2658	99	2.4	5.2

## Allogenic transplant patients

Infection rate	Patients	Infections	Median	75th percentile
Primary BSI / 1000 neutroenic days	3719	619	19.8	23.0
Pneumonia cases / 1000 neutropenic days	3719	333	8.7	18.2



**ONKO-KISS – Krankenhaus-Infektions-Surveillance-System auf Knochenmark- und Blutstammzell-Transplantationsabteilungen**  
 Berechnungszeitraum: Juli 2003 bis Juni 2008

## Referenzdaten für Knochenmark- und Blutstammzell- Transplantationsabteilungen

### Allogene Transplantationen

Anzahl Kliniken: 19  
 Anzahl Abteilungen: 20  
 Anzahl Patienten: 3.189  
 Anzahl Neutropenietage: 60.665  
 Anzahl Patienten mit NI: 778

### Verteilung Neutropeniedauer

Neutropeniedauer			
Gepoolt	25%-Quantil	50%-Quantil	75%-Quantil
19,0	17,8	18,5	20,3

### Inzidenzdichten über alle Patienten mit allogener Transplantation

Art der Infektion	Anzahl Infektionen	Inzidenzdichte			
		Gepoolt	25%-Quantil	50%-Quantil	75%-Quantil
Sepsis	525	8,7	7,8	9,9	12,2
Pneumonie	363	6,0	4,9	7,2	10,8

Inzidenzdichte = Anzahl Infektionen / Anzahl Neutropenie-Tage x 1000



# BSI cases

**Autologous tranplant patients**

**Incidence:  $8/2658 = 0,3 \%$**

**Allogenic tranplant patients**

**Incidence:  $31/3719 = 0.8 \%$**



Pathogen	n
C.krusei	8
C.albicans	5
C. tropicalis	3
C. glabrata	1
C. guilliermondi	1
C. parapsilosis	1
Candida spp.	15

**Only during neutropenic period !**


# Candida spp.



Often endogenous infections

selection following broad spectrum antibiotic usage

but also transmission via hands of HCW



In general the same prevention measures as used for bacterial infections

Only during neutropenic period !

Autologous transplant patients


Incidence :  $0/2658 = 0 \%$

Allogenic transplant patients

Incidence:  $11/3719 = 0.3 \%$

Pathogen	n
<i>A. fumigatus</i>	1
<i>A. flavus</i>	1
<i>Aspergillus</i> spp.	8
<i>Absidia</i> spp	1

Pneumonia cases



Molds

# 1. Surveillance

Hospitals caring for neutropenic patients should establish ongoing surveillance of IFI to detect increases in incidence

## Aspergillosis cases

It is necessary to perform a regular review of microbiological and pathology reports suggestive of infection.



# 1. Surveillance

EORTC/MSG defined 3 levels of diagnostic probabilities

„proven“

„probable“

„possible“

These criteria were designed for clinical research, but can also be applied to infection control surveillance.

De Pauw B et al. CID 2008; 46:1813-21

# 1. Surveillance

- it is not possible to reliably distinguish community-acquired from nosocomial cases
- arbitrary cut-off of 7 days has been used by some experts as an incubation period
- also nosocomial when 14 days post discharge

Partridge-Hinckley K et al. Mycopathologia 2009; 168: 329-37

# 1. Surveillance

## DENOMINATORS:

### A. Surveillance for the hematology/oncology department

- per number of patients with neutropenia/  
at least 10 days of neutropenia
- all patient days
  
- stratified according to type of therapy

### B. Surveillance for the whole hospital

- per 100 patients/ - per 1000 patient days


# Example: Surveillance

Year	Number of cases	Patient days	Incidence density (per 100 000 patient days)
2003	32	391 445	24
2004	16	407 007	15
2005	15	407 644	6
2006	7	415 980	5
2007	11	431.954	4

Graf K et al. BMC Infect Dis; in press

# Example: Surveillance

<b>proven</b>	<b>56</b>
<b>probable</b>	<b>25</b>
<b>possible</b>	<b>133</b>




<b>37</b>	<b>Solid organ transplantation</b>
<b>8</b>	<b>Bone marrow transplantation</b>
<b>10</b>	<b>Malignant tumors</b>
<b>26</b>	<b>Chronical organ diseases</b>

Graf K et al. BMC Infect Dis  
in press




## 2. Protective environment



## 2. Protective environment

FIGURE 1. Example of positive-pressure room control for protection from airborne environmental microbes\*†



**Source:** Adapted from Heating/Piping/Air Conditioning (HPAC) Engineering, October 2000, Penton Media, Inc.

**Note:** Stacked black boxes represent patient's bed. Long open box with cross-hatch represents supply air. Open boxes with single, diagonal slashes represent air exhaust registers. Arrows indicate directions of airflow.

- Positive airflow relative to the corridor
- high number of air changes per hour (> 12 ACH)
- Minimal leakage of air into the room


## 2. Protective environment

Central or point-of-use  
high-efficacy particulate air (HEPA)  
filters with 99.97 % efficacy for  
removing particles 0.3  $\mu\text{m}$  or larger

Aspergillus conidia  
(2.5-3.0  $\mu\text{m}$  diameter)







## 2. Protective environment

### Filter efficiency

Filters	Efficiency	(%)
1st	Low	20-40 %
2nd	Medium	90 %
3rd = HEPA*	High	99.97 % for removing particles $>0.3 \mu\text{m}$ in diameter.

HEPA = high-efficiency particulate air



# The evidence for HEPA filtration to prevent IFI: Our review

MAJOR ARTICLE

## The Influence of High-Efficiency Particulate Air Filtration on Mortality and Fungal Infection among Highly Immunosuppressed Patients: A Systematic Review

**Tim Eckmanns,<sup>1</sup> Henning Rüden,<sup>1</sup> and Petra Gastmeier<sup>2</sup>**

<sup>1</sup>Institute of Hygiene and Environmental Medicine, Charité–University Medicine Berlin, Berlin, and <sup>2</sup>Institute of Microbiology and Hospital Hygiene, Medical University Hanover, Hanover, Germany

Eckmanns et al. JID 2006; 193:1408–18

# Method

- 923 articles screened
- Two groups of studies: RCTs and non-RCTs (16 trials included; 8+8)
- Two endpoints:
  - mortality (9)
  - and fungal infection rate (10)

**Table 3. Results of meta-analyses of studies with death as the outcome.**

Authors, year of publication [reference]	Patients in rooms with HEPA/LAF ventilation, no.		Patients in rooms with no ventilation system, no.		Total patients, no.	RR (95% CI)	Mortality rate, %		
	Who died	Who survived	Who died	Who survived			With HEPA/LAF ventilation	Without ventilation	Overall
RCTs with death as the outcome									
Yates et al., 1973 [26]	11	24	17	35	87	0.96 (0.51–1.78)	31	33	32
Levine et al., 1973 [27]	1	21	9	29	60	0.19 (0.03–1.42)	5	24	17
Buckner et al., 1978 [24]	23	6	25	2	56	0.86 (0.69–1.06)	79	93	86
Storb et al., 1983 [25]	5	34	28	63	130	0.42 (0.17–1.00)	13	31	25
Petersen et al., 1987 [29]	13	36	12	38	99	1.11 (0.56–2.18)	27	24	25
Petersen et al., 1988 [28]	13	128	15	186	342	1.24 (0.61–2.51)	9	7	8
All	66	249	106	353	774	0.86 <sup>a</sup> (0.65–1.14)	21	23	22
Non-RCTs with death as the outcome									
Rodriguez et al., 1978 [24]	39	24	69	13	145	0.74 (0.59–0.91)	62	84	74
Schmeiser et al., 1988 [30]	1	25	0	15	41	1.78 (0.08–41.1)	4	0	2
Gamillscheg et al., 1991 [31]	16	9	11	9	45	1.16 (0.71–1.91)	64	55	60
All	56	58	80	37	231	0.87 <sup>a</sup> (0.60–1.25)	49	68	59

**NOTE.** CI, confidence interval; HEPA, high-efficiency particulate air; LAF, laminar airflow; non-RCT, nonrandomized controlled trial; RCT, randomized controlled trial; RR, relative risk.

<sup>a</sup> Pooled RR determined by the DerSimonian and Laird method.

**Table 4. Results of meta-analyses of studies with fungal infection as the outcome.**

Authors, year of publication [reference]	Patients in rooms with HEPA/LAF ventilation, no.		Patients in rooms with no ventilation system, no.		Total patients, no.	RR (95% CI)	Fungal infection rate, %		
	With fungal infection	Without fungal infection	With fungal infection	Without fungal infection			With HEPA/LAF ventilation	Without ventilation	Overall
RCTs with fungal infection as the outcome									
Levine et al., 1973 [27]	0	22	3	35	60	0.24 (0.013–4.48)	0	8	5
Schimff et al., 1975 [21]	0	24	1	18	43	0.27 (0.011–6.20)	0	5	2
Buckner et al., 1978 [24]	0	46	3	41	90	0.14 (0.0073–2.57)	0	7	3
Lohner et al., 1979 [32]	5	19	2	19	45	2.19 (0.47–10.1)	21	10	16
All	5	111	9	113	238	0.57 <sup>a</sup> (0.13–2.53)	4	7	6
Non-RCTs with fungal infection as the outcome									
Rodriguez et al., 1978 [23]	3	60	9	73	145	0.43 (0.12–1.54)	5	11	8
Navari et al., 1984 [33]	0	36	1	30	67	0.29 (0.012–6.83)	0	3	1
Rhame et al., 1984 [34]	9	158	12	55	234	0.30 (0.13–0.68)	5	18	9
Sherertz et al., 1987 [35]	0	39	14	74	127	0.077 (0.0047–1.25)	0	16	11
Withington et al., 1998 [36]	0	51	1	63	115	0.41 (0.017–10.0)	0	2	1
Oren et al., 2001 [37]	0	26	13	32	71	0.063 (0.0039–1.02)	0	29	18
All	12	370	50	327	759	0.29 <sup>a</sup> (0.15–0.54)	3	13	8

**NOTE.** CI, confidence interval; HEPA, high-efficiency particulate air; LAF, laminar airflow; non-RCT, nonrandomized controlled trial; RCT, randomized controlled trial; RR, relative risk.

<sup>a</sup> Pooled RR, determined by the DerSimonian and Laird method.

# Limitations

- Statistical homogeneity was considerable, huge differences in rates of infection and death
- studies performed over a very long period included (28 years)
- follow-up periods differed significantly
- Severity and duration of neutropenia?
- 3 studies used decontamination (with oral antibiotics)
- 2 studies used HEPA filtration only, the others in combination with LAF
- no study was blinded

Eckmanns et al. JID 2006; 193:1408–18



# The Influence of High-Efficiency Particulate Air Filtration on Mortality and Fungal Infection among Highly Immunosuppressed Patients: A Systematic Review

Tim Eckmanns,<sup>1</sup> Henning Rüden,<sup>1</sup> and Petra Gastmeier<sup>2</sup>

<sup>1</sup>Institute of Hygiene and Environmental Medicine, Charité–University Medicine Berlin, Berlin, and <sup>2</sup>Institute of Microbiology and Hospital Hygiene, Medical University Hanover, Hanover, Germany

## Conclusion

- Patients with BMT receive some benefit if they are placed in a protected environment
- Nevertheless the evidence is still somewhat ambiguous
- No final conclusion can be drawn from the data available

Eckmanns et al. JID 2006; 193:1408–18

# The evidence for HEPA filtration to prevent IFI: A new systematic review

Review

## Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis



Agata Schlesinger, Mical Paul, Anat Gafer-Gvili, Bina Rubinitz, Leonard Leibovici


To quantify the evidence for infection-control interventions among high-risk cancer patients and haematopoietic stem-cell recipients, we did a systematic review of prospective comparative studies. Protective isolation, including air quality control, prophylactic antibiotics, and barrier isolation (29 studies), brought about a significant reduction in all-cause mortality: risk ratio 0.60 (95% CI 0.50–0.72) at 30 days (number needed to treat [NNT] 20 [95% CI 14–33]) and 0.86 (95% CI 0.81–0.91) at the longest follow-up (up to 3 years; NNT 12 [95% CI 9–20]). Inclusion of prophylactic

*Lancet Infect Dis* 2009;  
9: 97–107  
Published Online  
December 17, 2008  
DOI:10.1016/S1473-  
3099(08)70284-6

Schlesinger et al. *Lancet Infect Dis* 2009; 9: 97-107

# Method

- Broader approach: “protective isolation” =
  - air quality control
  - prophylactic antibiotics
  - and barrier isolation
- Also RCTs and non-RCTs included
- mortality at day 30
- mortality at the longest follow-up



## Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis



Agata Schlesinger, Mical Paul, Anat Gafter-Gvili, Bina Rubinstein, Leonard Leibovici

To quantify the evidence for infection-control interventions among high-risk cancer patients and haematopoietic stem-cell recipients, we did a systematic review of prospective comparative studies. Protective isolation, including air quality control, prophylactic antibiotics, and barrier isolation (29 studies), brought about a significant reduction in all-cause mortality: risk ratio 0.60 (95% CI 0.50–0.72) at 30 days (number needed to treat [NNT] 20 [95% CI 14–33]) and 0.86 (95% CI 0.81–0.91) at the longest follow-up (up to 3 years; NNT 12 [95% CI 9–20]). Inclusion of prophylactic

Lancet Infect Dis 2009;  
9: 97–107  
Published Online  
December 17, 2008  
DOI:10.1016/S1473-  
3099(08)70284-6

## Conclusion

- “Air quality control, using HEPA filtration with or without other control measures, had only a modest effect on invasive mould infections and survival that did not reach significance.
- Its use should be probably reserved for patients at highest risk for invasive mould infections and for endemic or outbreak settings.

Schlesinger et al. Lancet Infect Dis 2009; 9: 97-107

# What patients should be hospitalized in protected rooms?

---

## Patients

- with allogenic transplants of haematopoietic stem cells or
- with severe neutropenia ( $< 100$  cells/mm<sup>3</sup>) of more than 1 week's duration

Ruiz-Camps I et al. Clin Micro Infect 2011; 17 (suppl 2), 1-24



# HEPA FILTRATION

WITH OR  
WITHOUT

LAF  
(= laminar  
airflow)



# Laminar airflow (LAF)

---

## PRO:

- involves much greater air changes
- helps to minimize opportunities for microorganism proliferation

## CON:

- much higher expense
- inconvenience to the patient due to noise and draughts

# Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?

- On balance, the additional expense and inconvenience of LAF does not appear to be justified.

H. Humphreys, J Hosp Infect 2004; 56: 93-100

# A survey in 180 centers 1999

(European Group for Bone and Marrow Transplantation; EBMT)

	HEPA	LAF
Allogenic HSCT	61 %	42 %
Autologous HSCT	47 %	24 %

Kruger WH et al. *J Hematother Stem Cell Res* 2001; 10: 895–903.


# A survey in 30 centers in Germany 2005

(ONKO-KISS group)

	HEPA	LAF
Allogenic HSCT	83 %	54 %
Autologous HSCT	53 %	28 %

Conrad et al. ECCMID 2006, Nice

# Fixed and portable HEPA filters



- Portable HEPA units are available that can filter air at a rate of 300–800 ft<sup>3</sup>/min.
- Portable HEPA filters are used temporarily in rooms with no general ventilation or to augment systems that cannot provide adequate airflow
- They should achieve the equivalent of  $\geq 12$  ACH.  
(An average room has approximately 1,600 ft<sup>3</sup> of airspace.)



### 3. Cleaning and disinfection measures for protected areas

The crucial point is designated and trained staff for cleaning!

The use of cleaning tools that may create dust or aerosols is absolutely contraindicated.

Almost all substances used for surface disinfection are able to eliminate fungi and fungal spores



# 4. Can patients at risk be moved around the hospital?

original article

*Annals of Oncology* 20: 1560–1564, 2009  
doi:10.1093/annonc/mdp034  
Published online 18 May 2009

## **A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients**


G. Maschmeyer<sup>1\*</sup>, S. Neuburger<sup>2</sup>, L. Fritz<sup>1</sup>, A. Böhme<sup>3</sup>, O. Penack<sup>4</sup>, R. Schwerdtfeger<sup>5</sup>,  
D. Buchheidt<sup>6</sup> & W.-D. Ludwig<sup>7</sup> on behalf of the Infectious Diseases Working Party (AGIHO) of the  
German Society of Haematology and Oncology

<sup>1</sup>Department of Haematology and Oncology, Ernst-von-Bergmann Clinic, Potsdam; <sup>2</sup>Department of Haematology and Oncology, Charité University Medical School, Campus Virchow-Klinikum, Berlin; <sup>3</sup>Department of Internal Medicine I, Johann-Wolfgang-Goethe-University Medical Centre, Frankfurt am Main; <sup>4</sup>Department of Haematology and Oncology, Charité University Medical School, Campus Benjamin Franklin, Berlin; <sup>5</sup>Centre for Bone Marrow and Stem Cell Transplantation, German Diagnostic Clinic DKD, Wiesbaden; <sup>6</sup>Department of Internal Medicine II, University Medical School Mannheim, Ruprecht-Karls-University of Heidelberg, Mannheim and <sup>7</sup>Department of Haematology, Oncology and Tumour Immunology, Robert Roessle-Clinic, Helios Clinic Berlin-Buch, Charité University Medical School, Berlin, Germany

Received 22 July 2008; revised 22 October 2008; accepted 26 January 2009

•Adults undergoing chemotherapy for acute leukaemia or allogeneic haematopoietic stem-cell transplantation (aHSCT).

41 patients (masks)  
39 patients control group



Maschmeyer et al.  
Ann Oncology 2009;  
20: 1560-64

This first randomised study on the use of well-fitting masks failed to show a reduction of invasive fungal infections.



## 5. Routine environmental cultures

Only useful in HEPA-filtered rooms to test the system

- once a year,
- occurrence of Aspergillosis cases
- construction work

Conidia count:  $< 0.1$  CFU/m<sup>3</sup>

## 5. Routine environmental cultures

Not useful in unfiltered areas;

Significant variation according to

- geographical area
- degree of activity in the area sampled
- temperature
- humidity

Condida count: usually between 10-25 CFU/m<sup>3</sup>

# 5. Routine environmental cultures

- No fixed rules for sampling
  - Various methods and equipment
  - Quantitative results





# 6. Infection control measures during construction projects



# Successful control of an outbreak of invasive aspergillosis in a regional haematology unit during hospital construction works<sup>☆</sup>

C.C. Chang<sup>a</sup>, A.C. Cheng<sup>a</sup>, B. Devitt<sup>b</sup>, A.J. Hughes<sup>a</sup>,  
P. Campbell<sup>b</sup>, K. Styles<sup>c</sup>, J. Low<sup>c</sup>, E. Athan<sup>a,\*</sup>

<sup>a</sup> *Department of Infectious Diseases, Geelong Hospital, Geelong, Victoria, Australia*

<sup>b</sup> *Clinical Haematology Unit, Geelong Hospital, Geelong, Victoria, Australia*

<sup>c</sup> *Infection Prevention Unit, Geelong Hospital, Geelong, Victoria, Australia*

Received 19 November 2007; accepted 7 February 2008

Available online 3 April 2008

Outbreak of six cases of nosocomial invasive aspergillosis (IA) in a haematology unit coinciding with major hospital construction works.




Figure 2 Timeline of invasive aspergillosis outbreak.

Among 18 following high-risk patients only one developed IA.



ELSEVIER

53 outbreaks  
involving 458 patients

REVIEW

## Nosocomial aspergillosis in outbreak settings

R-P. Vonberg\*, P. Gastmeier

*Institute for Medical Microbiology and Hospital*




Figure 1 Distribution of sources of nosocomial aspergillus outbreaks.

## 6. Infection control measures during construction projects

- set up a multidisciplinary team that includes infection control staff to coordinate proactive prevention measures to reduce exposure to fungal spores and **monitor adherence**
- provide education to HCW and the construction crew in immunocompromised patient care areas regarding aspergillosis
- dust control measures (dust barriers, safe air handling, negative pressure in construction work zones)
- water damage response plan to prevent fungal growth
- maintain surveillance for asperillosis cases



ELSEVIER



REVIEW

## Nosocomial aspergillosis in outbreak settings

R-P. Vonberg\*, P. Gastmeier

*Institute for Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Germany*

Volumetric air sampling performed during the course of epidemiologic investigations in 24 of the outbreaks noted spore counts ranging from 0 to 100 spores per cubic meter

Data from outbreak analyses have shown that it is impossible to provide a threshold below no problems are expected

# Poor correlation of *Aspergillus* spp. recovered from the environment and species isolated from patients with aspergillosis

## Explanations:

- Lack of a clearly defined incubation period for aspergillosis and the relationship to exposure within the hospital environment and subsequent infection
- Methods of air sampling used
- Broad diversity of *Aspergillus* spp. in the environment and the various methods used for typing of *Aspergillus*



## 7. Education

Health care workers must receive specific training on epidemiology and prevention measures to control and prevent infections



## 8. Guidelines for food

- Avoiding fresh fruits and vegetables that cannot be effectively washed.

Unpasteurized dairy products, cheese made from mold cultures, uncooked eggs, meat, fish tofu

Marr et al. Bone Marrow Transplantation 2009; 44:483-87

## 9. Guidelines for outpatient setting

- Avoiding activities such as gardening, mowing and vacuuming
- Avoid cleaning methods that disperse dust (family members)
- Leftover foods placed in the refrigerator should be discarded after 72 h
- Avoid fresh flowers and potted plants

## Empfehlung

Bundesgesundheitsbl 2010 · 53:357–388

DOI 10.1007/s00103-010-1028-9

Online publiziert: 20. März 2010

© Springer-Verlag 2010

Kommission für Krankenhaushygiene und Infektionsprävention  
beim Robert Koch-Institut (RKI)

# Anforderungen an die Hygiene bei der medizinischen Versorgung von immunsupprimierten Patienten

Empfehlung der Kommission für Kranken-  
haushygiene und Infektionsprävention beim  
Robert Koch-Institut (RKI)

## Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

I. Ruiz-Camps<sup>1</sup>, J. M. Aguado<sup>2</sup>, B. Almirante<sup>1</sup>, E. Bouza<sup>3</sup>, C. F. Ferrer-Barbera<sup>1</sup>, O. Len<sup>1</sup>, L. Lopez-Cerero<sup>4</sup>, J. L. Rodriguez-Tudela<sup>5</sup>, M. Ruiz<sup>6</sup>, A. Solé<sup>7</sup>, C. Vallejo<sup>8</sup>, L. Vazquez<sup>9</sup>, R. Zaragoza<sup>10</sup> and M. Cuenca-Estrella<sup>5</sup> GEMICOMED (Medical Mycology Study Group of SEIMC)

1) Infectious Diseases Department, Hospital de Vall d'Hebron, Barcelona, 2) Infectious Diseases Unit, Hospital Doce de Octubre, Madrid, 3) Clinical Microbiology and Infectious Diseases Department, Hospital Gregorio Marañón, Complutense University, Madrid, 4) Microbiology Department, Hospital Universitario Virgen de la Macarena, Seville, 5) Mycology Department, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, 6) TELSTAR Project SA, Madrid, 7) Lung Transplant and Cystic Fibrosis Unit, Hospital Universitario la FE, Valencia, 8) Haematology Department, Hospital Universitario Central de Asturias, Oviedo, 9) Haematology Department, Hospital Clínico, Salamanca and 10) Intensive Medicine Department, Hospital Universitario Dr Peset, Valencia, Spain

Ruiz-Camps et al. Clin Micro Infect 2011; 17 (Supl 2):1-24.